Supplementary Materials for FY2026 First Half Financial Results

Overview of Results

For the first half of FY2026, net sales were 32,395 million yen, operating income was 1,743 million yen, ordinary income was 1,434 million yen, and interim net income was 1,041 million yen. Net sales increased by 3.7% year-over-year, and all profit indicators achieved significant increases. Based on first-half results, the full-year forecasts have been revised upward to net sales of 64,800 million yen, operating income of 2,000 million yen, ordinary income of 1,500 million yen, and net income attributable to owners of parent of 1,500 million yen.

Outlook and Factors

Strong performance of products such as Rixell, Celnilton, and Dopacol is expected to continue. However, the impact of rising raw material prices due to Middle East conditions is expected to become apparent in the second half, leading to a deterioration in cost ratios. R&D expenses are expected to increase, but the full-year forecast has been revised upward based on first-half results. The interim dividend will be 45 yen, and the year-end dividend will be increased by 1 yen to 46 yen, with a policy to continue progressive dividends through FY2030.